Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Ross Camidge

Showing results (41-50 of 317) with videos related to

Pageof 32
Sort By:
Nature Reviews. Clinical Oncology|July 2, 2014
Acquired resistance to TKIs in solid tumours: learning from lung cancerD Ross Camidge, William Pao, Lecia V Sequist
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2013
Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancerEiko Theodora Browning, Andrew James Weickhardt, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 29, 2015
Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection PressureJoel P Womack, Marileila Varella-Garcia, D Ross Camidge
Journal of Thoracic Disease|July 27, 2012
A time to test, a time to treatAndrew J Weickhardt, Robert C Doebele, D Ross Camidge
The Lancet. Oncology|September 2, 2008
Targeted manipulation of apoptosis in cancer treatmentJustin A Call, S Gail Eckhardt, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 14, 2016
Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib TreatmentSinead A Noonan, Peter B Sachs, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 6, 2024
The Use of Investigator-Assigned Subjective or Judgmental Efficacy and Toxicity Reporting in Early Phase Clinical Trials of Lung Cancer TreatmentsWilliam J Phillips, Alexander S Watson, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 10, 2025
Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant ChemoimmunotherapyWilliam J Phillips, D Ross Camidge, Paul Wheatley-Price
The New England Journal of Medicine|May 20, 2016
Update to Rociletinib Data with the RECIST Confirmed Response RateLecia V Sequist, Jean-Charles Soria, D Ross Camidge
Nature Reviews. Clinical Oncology|February 6, 2019
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLCD Ross Camidge, Robert C Doebele, Keith M Kerr
Pageof 32

Showing results (41-50 of 317) with videos related to

Sort By:
Pageof 32
Nature Reviews. Clinical Oncology|July 2, 2014
Acquired resistance to TKIs in solid tumours: learning from lung cancerD Ross Camidge, William Pao, Lecia V Sequist
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2013
Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancerEiko Theodora Browning, Andrew James Weickhardt, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 29, 2015
Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection PressureJoel P Womack, Marileila Varella-Garcia, D Ross Camidge
Journal of Thoracic Disease|July 27, 2012
A time to test, a time to treatAndrew J Weickhardt, Robert C Doebele, D Ross Camidge
The Lancet. Oncology|September 2, 2008
Targeted manipulation of apoptosis in cancer treatmentJustin A Call, S Gail Eckhardt, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 14, 2016
Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib TreatmentSinead A Noonan, Peter B Sachs, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 6, 2024
The Use of Investigator-Assigned Subjective or Judgmental Efficacy and Toxicity Reporting in Early Phase Clinical Trials of Lung Cancer TreatmentsWilliam J Phillips, Alexander S Watson, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 10, 2025
Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant ChemoimmunotherapyWilliam J Phillips, D Ross Camidge, Paul Wheatley-Price
The New England Journal of Medicine|May 20, 2016
Update to Rociletinib Data with the RECIST Confirmed Response RateLecia V Sequist, Jean-Charles Soria, D Ross Camidge
Nature Reviews. Clinical Oncology|February 6, 2019
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLCD Ross Camidge, Robert C Doebele, Keith M Kerr
Pageof 32